Cargando…
Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity
Hepatocellular carcinoma (HCC) accounts for most of primary liver cancer, of which five-year survival rate remains low and chemoprevention has become a strategy to reduce disease burden of HCC. We aim to explore the in vivo chemopreventive effect of an organoselenium-containing compound butaselen (B...
Autores principales: | Zheng, Xiaoqing, Ma, Weiwei, Sun, Ruoxuan, Yin, Hanwei, Lin, Fei, Liu, Yuxi, Xu, Wei, Zeng, Huihui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633849/ https://www.ncbi.nlm.nih.gov/pubmed/28965082 http://dx.doi.org/10.1016/j.redox.2017.09.014 |
Ejemplares similares
-
Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress
por: Dong, Chaoran, et al.
Publicado: (2016) -
Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study
por: Ye, Suofu, et al.
Publicado: (2019) -
Therapeutic Effects of an Inhibitor of Thioredoxin Reductase on Liver Fibrosis by Inhibiting the Transforming Growth Factor-β1/Smads Pathway
por: Jiao, Wenxuan, et al.
Publicado: (2021) -
Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
por: Wu, Xuping, et al.
Publicado: (2021) -
Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer
por: Peng, Wei, et al.
Publicado: (2019)